DUSP6 and melanoma: These cells simultaneously became more resistant to the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib, suggesting that the modulation of the DUSP6/ERK5 signaling pathway by MIR211 is related to the development of BRAF/MEK inhibitor resistant melanoma (68).